The use of TNF-α inhibitors (monoclonal antibody Adalimumab, chimeric monoclonal antibody Infliximab, and TNF-α specific monoclonal antibody fragment Certolizumab pegol) as therapeutic agents for transplant recipients has recently been investigated for efficacy and safety in 6 renal transplant patients for treating ankylosing spondylitis (AS) (43). The gene discussed is TNF; the disease is ankylosing spondylitis.